



2007/2008 Interim Report Card for the Ontario Drug Benefit Program

Provincial Health Expenditures - Total \$42.9 Billion, Ontario 2007




Source: Forecast from the Canadian Institute for Health Information (CIHI), 2007

Provincial Health Expenditures Ontario, 1975-2007



Source: Actual and forecasted data from the Canadian Institute for Health Information (CIHI), 2007


Ontario 2007 Drug Costs – Total \$9.4 Billion Public, Private & Beneficiary Costs




Source: Forecast from the Canadian Institute for Health Information (CIHI), 2007

Note: Other Public Programs include NIHB, Veteran's programs, and misc. Federal Programs (e.g. RCMP, etc.)


ODB Utilizing Beneficiaries & Claims 1997/98 – 2007/08



Age Breakdown of ODB Utilizing Beneficiaries 1997/98 vs. 2007/08




<65	840K
Trillium	37K
65+	1,310K
Total	2,187K



<65	566K
Trillium	151K
65+	1,616K
Total	2,333K

Trillium Applications* & Processing Time, 1996 – 2007 Benefit Years**




* Number of applications represents households, not individuals


** Trillium benefit year starts August 1 and ends July 31 the following year

Beneficiary Distribution & Government Share, by Age, 2007/08


Distribution of beneficiaries
by age group



Government share per beneficiary
by age group




Top-10 Therapeutic Classes* by Number of Users, 2007/08



* Based on the classification system of the American Hospital Formulary Service of the American Society of Health-System Pharmacists (AHFS-ASHP).


Top-10 Therapeutic Classes by Drug Cost, 2007/08



* Does not include New Drug Funding Program (NDFP) expenditures, administered on behalf of the MOHLTC by Cancer Care Ontario (CCO).
For 2007/2008 NDFP expenditures = \$162.5million


Cost Concentration, 2007/08

From Least to Most Costly Beneficiary




* RxCost = Drug Cost + Markup + Dispensing fee

Brand vs. Generic RxCost 1997/98 – 2007/08



Brand vs. Generic RxCost

Annual Growth, 1997/98 – 2007/08



Top-10 Chemicals, 2007/08


by Number of Utilizing Beneficiaries (thousands)

Rk	Drug Name	Class	Utilizing Benef.	% Utilizing Benef.
1	Atorvastatin (Lipitor)	Cardiovascular	496K	21.3%
2	Acetaminophen & Caffeine & Codeine (Tylenol #3)	Central Nervous System	415K	17.8%
3	Ramipril (Altace)	Cardiovascular	368K	15.8%
4	Amoxicillin (Amoxil)	Anti-infective	338K	14.5%
5	Hydrochlorothiazide	Electrolytic, Caloric & Water Balance	320K	13.7%
6	Diagnostic Agent - Diabetes	Diagnostic Agents	319K	13.7%
7	Levothyroxine sodium (Synthroid)	Hormones & Subst.	287K	12.3%
8	Amlodipine Besylate (Norvasc)	Cardiovascular	285K	12.2%
9	Salbutamol (Ventolin)	Autonomic Agents	277K	11.9%
10	Metformin HCl (Glucophage)	Hormones & Substitutes	272K	11.7%


Top-10 Chemicals by Drug Cost 2007/08

Rk	Drug Name	Class	Drug Cost	% Total Drug Cost
1	Atorvastatin (Lipitor)	Cardiovascular	288M	9.0%
2	Amlodipine Besylate (Norvasc)	Cardiovascular	132M	4.1%
3	Diagnostic Agent - Diabetes	Diagnostic Agents	107M	3.3%
4	Olanzapine (Zyprexa)	Central Nervous System	76M	2.4%
5	Rabeprazole Sodium (Pariet)	Gastrointestinal	68M	2.1%
6	Pantoprazole Sodium (Pantoloc) - LU	Gastrointestinal	64M	2.0%
7	Salmeterol Xinafoate & Fluticasone Propionate (Advair) - LU	Autonomic Agents	56M	1.7%
8	Ramipril (Altace)	Cardiovascular	54M	1.7%
9	Donepezil HCl (Aricept) - LU	Autonomic Agents	53M	1.7%
10	Oxycodone (Oxycontin) - LU	Central Nervous System	49M	1.5%
TOTAL Top-10			\$954M	29.6%


Fastest Growing Brand Products, by Drug Cost, 2006/07 – 2007/08



Special Drugs Program Cost 1997/98-2007/08



Exceptional Access Program (EAP) Beneficiaries 1998/99 - 2007/08




	98/99	99/00	00/01	01/02	02/03	03/04	04/05	05/06	06/07	07/08
Beneficiaries ('000)	12.4	19.8	27.8	37.3	57.8	64.9	83.6	98.5	106.2	87.2
% of Overall ODB	0.6%	0.9%	1.3%	1.8%	2.8%	3.0%	3.9%	4.4%	4.7%	3.70%


Exceptional Access Program (EAP)

Government Cost

1998/99 - 2007/08




Monthly EAP Requests * April 1997 – March 2008



* Each Drug Identification Number (DIN/PIN) is counted as a request.

EAP Requests & Approval Rate

FY 1999/00 – 2007/08



* approved on first review; does not include approvals subsequent to provision of additional information from requesting physicians

EAP Top-10 Requested Drugs by Volume, FY 2007/08

Rk	Drug	Requests	Approved	% Approved*	Gov't Cost
1	Plavix	53,331	46,346	86.9	\$37.1M
2	Lyrica	14,023	4,106	29.3	\$1.3M
3	Gabapentin	8,713	3,980	45.7	\$1.3M
4	Remicade	8,124	5,544	68.2	\$37.3M
5	Enbrel	5,928	4,245	71.6	\$25.3M
6	GlucNorm	4,246	2,582	60.8	\$1.1M
7	Neupogen	3,921	2,410	61.5	\$9.8M
8	Concerta	3,766	1,144	30.4	\$0.6M
9	Strattera	3,150	942	30.0	\$0.4M
10	Eprex	3,007	2,221	73.9	\$4.8M
Top-10 Total		108,209	73,520	68.0	\$119M

* approved on first review

EAP Top-10 Requested Drugs by Government Costs, 2007/08

Rk	Drug	Beneficiaries	Claims	Gov't Cost
1	Remicade	1,808	9,841	\$37.3
2	Plavix	49,321	465,048	\$37.1
3	Enbrel	1,783	13,315	\$25.3
4	Neupogen	1,513	5,214	\$9.8
5	Humira	727	5,271	\$9.6
6	Rebif	533	4,659	\$8.8
7	Tracleer	214	1,940	\$7.4
8	Pegasys RBV	723	4,839	\$6.6
9	Pegetron (Redipen)	672	4,049	\$6.1
10	Avonex	394	3,404	\$5.7
Total Top 10 EAP		57,440	517,580	\$153.5M
% Top 10 EAP / Total EAP		65.9%	66.7%	68.4%